Maridebart cafraglutide (also known as MariTide;[1] developmental name AMG 133) is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). Namely, MariTide consists of a monoclonal antibody against GIPR conjugated to two peptidic GLP-1R agonist molecules via amino acid linkers.[2] In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.[3][4][5]
| Clinical data | |
|---|---|
| Other names | AMG 133 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
References
edit- ^ Beasley, Deena (2024-02-06). "Amgen taking different path to weight loss windfall". Reuters. Retrieved 2024-03-06.
- ^ Véniant, Murielle M.; Lu, Shu-Chen; Atangan, Larissa; Komorowski, Renee; Stanislaus, Shanaka; Cheng, Yuan; Wu, Bin; Falsey, James R.; Hager, Todd; Thomas, Veena A.; Ambhaikar, Malhar; Sharpsten, Lucie; Zhu, Yineng; Kurra, Vamsi; Jeswani, Rohini (2024-02-05). "A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings". Nature Metabolism. 6 (2): 290–303. doi:10.1038/s42255-023-00966-w. ISSN 2522-5812. PMC 10896721. PMID 38316982.290-303&rft.date=2024-02-05&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896721#id-name=PMC&rft.issn=2522-5812&rft_id=info:pmid/38316982&rft_id=info:doi/10.1038/s42255-023-00966-w&rft.aulast=Véniant&rft.aufirst=Murielle M.&rft.au=Lu, Shu-Chen&rft.au=Atangan, Larissa&rft.au=Komorowski, Renee&rft.au=Stanislaus, Shanaka&rft.au=Cheng, Yuan&rft.au=Wu, Bin&rft.au=Falsey, James R.&rft.au=Hager, Todd&rft.au=Thomas, Veena A.&rft.au=Ambhaikar, Malhar&rft.au=Sharpsten, Lucie&rft.au=Zhu, Yineng&rft.au=Kurra, Vamsi&rft.au=Jeswani, Rohini&rft_id=https://www.nature.com/articles/s42255-023-00966-w&rfr_id=info:sid/en.wikipedia.org:Maridebart cafraglutide" class="Z3988">
- ^ Hammoud, Rola; Drucker, Daniel J. (April 2023). "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1". Nature Reviews Endocrinology. 19 (4): 201–216. doi:10.1038/s41574-022-00783-3. ISSN 1759-5037.201-216&rft.date=2023-04&rft_id=info:doi/10.1038/s41574-022-00783-3&rft.issn=1759-5037&rft.aulast=Hammoud&rft.aufirst=Rola&rft.au=Drucker, Daniel J.&rft_id=https://www.nature.com/articles/s41574-022-00783-3&rfr_id=info:sid/en.wikipedia.org:Maridebart cafraglutide" class="Z3988">
- ^ Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240.231-243&rft.date=2021-07-03&rft_id=info:doi/10.1080/14728214.2021.1947240&rft.aulast=Jepsen&rft.aufirst=Mathies M.&rft.au=Christensen, Mikkel B.&rfr_id=info:sid/en.wikipedia.org:Maridebart cafraglutide" class="Z3988">
- ^ Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (1 March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939. ISSN 0196-9781.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |